Bristol Myers Squibb’s second quarter results were marked by strong contributions from its growth portfolio, leading to a positive market reaction. Management credited double-digit sales increases from key products such as Reblozyl, Breyanzi, Camzyos, Opdualag, and Qvantig with driving overall business momentum. CEO Chris Boerner emphasized that disciplined execution and a broadening product mix supported both revenue and margin expansion, while Chief Financial Officer David Elkins noted that “performance is also supported by disciplined investment in growth-oriented initiatives.” The company also highlighted progress in its oncology and cardiovascular franchises, demonstrating resilience across both new and legacy assets.
Is now the time to buy BMY? Find out in our full research report (it’s free for active Edge members).
Bristol-Myers Squibb (BMY) Q2 CY2026 Highlights:
- Revenue: $12.97 billion vs analyst estimates of $11.5 billion (5.7% year-on-year growth, 12.9% beat)
- Adjusted EPS: $2.04 vs analyst estimates of $1.60 (27.7% beat)
- The company lifted its revenue guidance for the full year to $49.5 billion at the midpoint from $46.75 billion, a 5.9% increase
- Management raised its full-year Adjusted EPS guidance to $6.88 at the midpoint, a 10.9% increase
- Operating Margin: 31%, up from 18.5% in the same quarter last year
- Market Capitalization: $130 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Bristol-Myers Squibb’s Q2 Earnings Call
- Geoffrey Meacham (Citibank): asked about timelines for ADEPT and milvexian studies. Chief Medical Officer Cristian Massacesi explained delays are due to slower event accrual and greater patient quality controls, not changes in scientific rationale.
- Christopher Schott (JPMorgan): questioned what efficacy thresholds for milvexian would make it a large commercial opportunity. Chief Commercialization Officer Adam Lenkowsky emphasized the need for a superior bleeding profile and confidence in broad market adoption if the safety advantage holds.
- Evan Seigerman (BMO Capital Markets): inquired about business development priorities. CEO Chris Boerner highlighted interest in assets within familiar therapeutic areas, focusing on scientific and financial fit, while Massacesi stressed the importance of novel targets and delivery modalities.
- Emily Field (Barclays): asked about physician adoption and dose optimization for Cobenfy in schizophrenia and confidence in Sotyktu for lupus. Lenkowsky described ongoing education efforts and upcoming readouts as potential catalysts for further growth.
- Asad Haider (Goldman Sachs): sought context on expectations for admilparant’s upcoming readout in pulmonary fibrosis. Massacesi and Lenkowsky discussed its potential to improve efficacy and tolerability versus current therapies and the growing second-line treatment market.
Catalysts in Upcoming Quarters
Over the coming quarters, the StockStory team will closely monitor (1) pivotal clinical trial readouts for admilparant in pulmonary fibrosis and iberdomide in multiple myeloma, (2) the continued adoption of new therapies like Qvantig, Breyanzi, and Camzyos in core markets, and (3) the impact of AI integration on R&D productivity and the efficiency of clinical development. Progress on these fronts will be central to Bristol Myers Squibb’s ability to sustain momentum and deliver on upgraded guidance.
Bristol-Myers Squibb currently trades at $63.69, in line with $63.10 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.